Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. (Q33225025)

24 July 2017

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. (English)

1 reference

24 July 2017

7

Josephine M Egan

1 reference

24 July 2017

2

Olga Carlson

1 reference

24 July 2017

Michael J Theodorakis

1

1 reference

24 July 2017

Spyros Michopoulos

3

1 reference

24 July 2017

Máire E Doyle

4

1 reference

24 July 2017

Magdalena Juhaszova

5

1 reference

24 July 2017

Kalliopi Petraki

6

1 reference

24 July 2017

11 October 2005

1 reference

American Journal of Physiology - Endocrinology and Metabolism

24 July 2017

1 reference

24 July 2017

290

1 reference

24 July 2017

3

1 reference

24 July 2017

E550-9

1 reference

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

24 July 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Gastrointestinal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glucose-dependent insulin release from genetically engineered K cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Immunocytochemical evidence for co-expression of Type III IP3 receptor with signaling components of bitter taste transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

21 January 2018

Glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

21 January 2018

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Thrombin stimulates glucose transport in human platelets via the translocation of the glucose transporter GLUT-3 from alpha-granules to the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Role of oxidative stress in advanced glycation end product-induced mesangial cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Gastric inhibitory polypeptide: the neglected incretin revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Is glucagon-like peptide 1 an incretin hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glicentin Immunoreactive Cells: Their Relationship to Glucagon-Producing Cells*

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Glucose-sensing in glucagon-like peptide-1-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

A human cellular model for studying the regulation of glucagon-like peptide-1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Gastric inhibitory peptide-like immunoreactivity in glucagon and glicentin cells: properties and origin. An immunocytochemical study using several antisera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

GIP biology and fat metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00326.2004

10.1152/AJPENDO.00326.2004

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference